JP2025508402A - 医薬製剤 - Google Patents

医薬製剤 Download PDF

Info

Publication number
JP2025508402A
JP2025508402A JP2024548368A JP2024548368A JP2025508402A JP 2025508402 A JP2025508402 A JP 2025508402A JP 2024548368 A JP2024548368 A JP 2024548368A JP 2024548368 A JP2024548368 A JP 2024548368A JP 2025508402 A JP2025508402 A JP 2025508402A
Authority
JP
Japan
Prior art keywords
weight
amount
amino
pharma
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508402A5 (cg-RX-API-DMAC7.html
Inventor
グルラジャン,ビンドゥーマドハーヴァン
レーノー,エメリック
ローグ,ヴィンセント
ロワルカー,ロイット
パワル,ヨゲシュ
サワイ,トゥーシャー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2025508402A publication Critical patent/JP2025508402A/ja
Publication of JP2025508402A5 publication Critical patent/JP2025508402A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024548368A 2022-02-21 2023-02-20 医薬製剤 Pending JP2025508402A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202211009181 2022-02-21
IN202211009181 2022-02-21
PCT/IB2023/051532 WO2023156979A1 (en) 2022-02-21 2023-02-20 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
JP2025508402A true JP2025508402A (ja) 2025-03-26
JP2025508402A5 JP2025508402A5 (cg-RX-API-DMAC7.html) 2026-02-20

Family

ID=85476156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548368A Pending JP2025508402A (ja) 2022-02-21 2023-02-20 医薬製剤

Country Status (11)

Country Link
US (1) US20250161223A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482471A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508402A (cg-RX-API-DMAC7.html)
KR (1) KR20240150600A (cg-RX-API-DMAC7.html)
CN (1) CN118715005A (cg-RX-API-DMAC7.html)
AU (1) AU2023221615A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251234A1 (cg-RX-API-DMAC7.html)
IL (1) IL314206A (cg-RX-API-DMAC7.html)
MX (1) MX2024009967A (cg-RX-API-DMAC7.html)
TW (1) TW202342040A (cg-RX-API-DMAC7.html)
WO (1) WO2023156979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119789849A (zh) * 2022-08-31 2025-04-08 阿斯利康(瑞典)有限公司 药物制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
EP3923940B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CN113382774A (zh) 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和krasg12c抑制剂的药物组合
US12343344B2 (en) 2019-02-12 2025-07-01 Novartis Ag Pharmaceutical combination comprising TNO155 and ribociclib
US20230090389A1 (en) 2020-02-28 2023-03-23 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor

Also Published As

Publication number Publication date
CA3251234A1 (en) 2023-08-24
WO2023156979A1 (en) 2023-08-24
US20250161223A1 (en) 2025-05-22
MX2024009967A (es) 2024-08-26
TW202342040A (zh) 2023-11-01
IL314206A (en) 2024-09-01
AU2023221615A1 (en) 2024-07-25
EP4482471A1 (en) 2025-01-01
KR20240150600A (ko) 2024-10-15
CN118715005A (zh) 2024-09-27

Similar Documents

Publication Publication Date Title
JP7550393B2 (ja) 低分子egfr阻害剤を含む医薬組成物及びその製造方法
JP6503317B2 (ja) C−met調節剤の薬学的組成物
JP6577143B2 (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
TWI845657B (zh) (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法
US20140186407A9 (en) C-Met Modulator Pharmaceutical Compositions
JP2018177815A (ja) エスシタロプラム医薬組成物
JP7665702B2 (ja) アキシチニブを含有する医薬組成物
WO2020186812A1 (zh) 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用
KR20240150600A (ko) 약학적 제형
WO2023238929A1 (ja) ピミテスピブを含有する医薬組成物
JP7370126B2 (ja) エルロチニブを有効成分とする医薬錠剤
KR101739731B1 (ko) 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
JP7370125B2 (ja) エルロチニブを有効成分とする医薬錠剤
KR20240016319A (ko) 프탈라지논 유도체를 이용한 장애 치료 방법
TWI912013B (zh) 晶體、藥物組合物及其製備方法和應用
KR20180103090A (ko) 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물의 제조 방법
JP2020147542A (ja) ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する多層錠
JP7370124B2 (ja) エルロチニブを有効成分とする医薬錠剤
WO2025252098A1 (zh) Glp-1受体激动剂的口服药物组合物及其制备方法
KR20180103089A (ko) 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물
WO2024251197A1 (zh) Eed抑制剂固体分散体、包含其的口服制剂及其制备方法
JP2021165266A (ja) ビルダグリプチン錠剤およびその製造方法
JP2019507151A (ja) ピロロ縮合複素6員環化合物を含有する医薬組成物
WO2025140560A1 (zh) 间变性淋巴瘤激酶抑制剂的药物组合物及其制备方法
HK40123031A (en) Crystal, pharmaceutical composition, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260212